6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis

Drug Category : Array
Conference Category : Array
Lead Author : Fox E, et al.
Published Date : 01/02/2018
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/2018-ACTRIMS-Ublituximab-Poster.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top